News

Flavor is predictable: With FlavorMiner.
FlavorMiner is the name of the tool recently developed by IPB chemists and partners from Colombia. Based on machine learning, the program can predict the most important taste…

Read more

During the Leibniz Conference on Bioactive Compounds, on April 9, 2025, the “Leibniz Drug of the Year 2025” has been awarded to Dr. Ibrahim Morgan, Dr. Robert Rennert, Dr. Tuvshinjargal Budragchaa und Prof. Dr. Ludger…

Read more

A joint press release of the Leibniz Institute for Food Systems Biology at the Technical University of Munich and the Leibniz Institute of Plant Biochemistry

Read more

Our 10th Leibniz Plant Biochemistry Symposium will take place on May 7 and 8 at the Leibniz Institute of Agricultural Development and Transition Economies (IAMO). This year's theme will be new methods and research approaches…

Read more

Around 300,000 guests visited this year's Berlin International Green Week, which took place from January 17-26. Arianne Schnabel was one of the 1,400 exhibitors who presented their products, projects and ideas at this,…

Read more

At the end of 2024, the NMR lab at the IPB was upgraded with the installation of a new Bruker AVANCE NEO spectrometer. This state-of-the-art system features an 16.4T (700MHz) Ascend magnet and helium-cooled cryoprobes (5mm…

Read more

The IPB is automating its administrative processes. Our Administrative Director Peter Zuber and the Institute's Manager for Digital Transformation have successfully applied for funding from Saxony-Anhalt's Ministry of…

Read more

The 16th United Nations World Conference on Nature (COP16) took place from October 21 to November 1, 2024 in Cali, Colombia. Around 23,000 delegates from 196 countries came together for this event, primarily to discuss the im…

Read more

In a joint recruitment between the Martin-Luther University Halle-Wittenberg (MLU) in the Faculty of Natural Sciences I – Biosciences and the Leibniz Institute of Plant Biochemistry (IPB) the following position is to be…

Read more

Selective cancer drugs in the pipeline.

Peptide-drug conjugates (PDCs) are increasingly becoming the focus of cancer research, as they enable the targeted release of anticancer agents in tumor tissue. Like the established…

Read more

This page was last modified on 11 Feb 2025 .